Company
BridGene Biosciences
| Industry | leader in the discovery and development of small molecule drugs for traditionally “hard-to-drug” targets |
|---|
Funding raised
| Company | Round | Date |
|---|---|---|
| BridGene Biosciences | Series B+ | 2025-10-16 |
Company
| Industry | leader in the discovery and development of small molecule drugs for traditionally “hard-to-drug” targets |
|---|
| Company | Round | Date |
|---|---|---|
| BridGene Biosciences | Series B+ | 2025-10-16 |